{"entity":{"id":"paper-yee-endogenous-t-cell-therapy-cancer-j-2015","kind":"paper","name":"Endogenous T-Cell Therapy: Clinical Experience","aka":[],"tldr":"A review that names and describes endogenous T-cell therapy: growing the rare cancer-recognising T cells from a patient's blood and giving them back, as an alternative to tumour-derived or genetically engineered T cells.","summary":"The review sets out three approaches to adoptive T-cell transfer (tumour-infiltrating lymphocytes, CAR- or TCR-engineered lymphocytes, and expansion of low-frequency endogenous T cells from peripheral blood) and describes the third, ETC therapy, its isolation and expansion methods and its clinical experience (Cancer Journal 2015).","asOf":"2026-11-05","links":[{"label":"DOI 10.1097/PPO.0000000000000158","url":"https://doi.org/10.1097/PPO.0000000000000158"},{"label":"PubMed 26588682","url":"https://pubmed.ncbi.nlm.nih.gov/26588682/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":["the-cancer-journal"],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"journal":"The Cancer Journal","year":2015,"doi":"10.1097/PPO.0000000000000158","pmid":"26588682","authors":"Yee C, Lizee G, Schueneman AJ.","paperType":"review","findings":["Defines endogenous T-cell (ETC) therapy as the isolation and expansion of low-frequency tumour-reactive T cells from peripheral blood.","Argues that ETC trials can be started rapidly once a tumour-associated target epitope is identified, which could allow personalised antigen-specific T-cell therapy for almost any solid tumour."],"whatItMeans":"The paper gives the approach its name and makes the case for it beyond melanoma.","caveats":["Narrative review by the method's developers."]},"route":"/key-papers/paper-yee-endogenous-t-cell-therapy-cancer-j-2015/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}],"journal":[{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/"}]}}